Talaris Therapeutics has raised $115 million in financing, which will be used to support the clinical development of its lead therapeutic candidate, FCR001, designed to promote immune tolerance and allow patients to stop taking immunosuppressive medications after a transplant. The newly raised funds…
News
A Phase 3 trial testing iloprost, known as CIVI030, for the treatment of Raynaud’s phenomenon due to scleroderma has resumed patient enrollment, according to the therapy’s developer, CiVi Biopharma. The trial (NCT04040322), named AURORA and sponsored by Civi’s subsidiary Eicos Sciences, launched…
Same But Different, a nonprofit U.K. group that uses art for social change, is inviting people to choose their favorite photographs in a calendar contest to heighten awareness of rare diseases, including amyotrophic lateral sclerosis (ALS). The organization’s panel of judges has pared the number of contest submissions…
Following the onset of the COVID-19 pandemic, people with scleroderma experienced substantial increases in anxiety, but not depression, a new study has found. Results also show that older patients and those with greater financial resources experienced smaller increases in anxiety. The study, “Changes in mental health…
A new computer software, called Capillary.io, uses artificial intelligence (AI) to aid in diagnosing scleroderma at early disease stages. The tool, developed in partnership with the Sociedad Española de Medicina Interna (SEMI), was designed specifically to improve a non-invasive, highly sensitive and inexpensive technique — called nailfold capillaroscopy — used by…
A protein known as TL1A drives lung fibrosis, or scarring, in scleroderma, a new study suggests. The findings suggest that blocking TL1A could be an effective therapeutic strategy in scleroderma and other conditions characterized by lung fibrosis, including severe asthma, and idiopathic pulmonary fibrosis. Titled, “…
Muscular involvement is linked with more severe symptoms in people with scleroderma, affecting heart, lungs and the digestive system, a study from China reports. These patients are likely to have a worse disease prognosis and poorer survival, its data show. The study “Myopathy is a Risk Factor for…
Bob Saget will return to host the 34th annual Cool Comedy – Hot Cuisine fundraiser, benefiting the Scleroderma Research Foundation (SRF), on Sunday, Oct. 18. The comedian will be joined by celebrity chef and restaurateur Susan Feniger as co-host of the now online event.
Rituximab, in combination with CellCept (mycophenolate mofetil), reverses the decline in lung function in people with interstitial lung disease (ILD) associated with scleroderma (SSc) who did not respond to immunosuppressant therapies, a study suggested. The study, “…
Detailed characteristics of 12 cases of lung cancer in people with scleroderma were described in a new study. Notably, all patients were women and most had interstitial lung disease (ILD). The study, “Clinicopathological characteristics of lung cancer in patients with systemic sclerosis,” was published…
Recent Posts
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc